Patients treated with ProTrans in phase II of the clinical trial

NextCell Pharma AB ("NextCell" or the "Company") has been selected as the only Swedish company to participate in the EU-Japan Biotech Business Mission 2026. In parallel, the Company is strengthening its local presence in Hong Kong by establishing an office and becoming a member of the Hong Kong-Shenzhen Innovation and Technology Park (HSITP), effective 1 September. NextCell will also participate as a Founding Partner in the Nordic Future Health Pavilion at BIOHK 2026, held 9–12 September.

NextCell Pharma AB (publ) (“NextCell” or the “Company”) publishes its Interim report for the first quarter 2026. The report is available on the company´s website: www.nextcellpharma.com. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period last year.  Please note that, as of 2025, the Company’s financial year corresponds to the calendar year.

On Wednesday, 27 May 2026, the Annual General Meeting of NextCell Pharma AB (publ), reg. no. 556965-8361 (“NextCell” or the “Company”), was held. A summary of the resolutions adopted at the Annual General Meeting is set out below. All resolutions were adopted with the required majority. For more detailed information regarding the content of the resolutions, reference is made to the notice convening the Annual General Meeting and the complete proposals for resolutions, which have previously been published and are available on the Company’s website, www.nextcellpharma.com.

NextCell Pharma AB ("NextCell" or "the Company") today announces that in collaboration with FUJIFILM Biosciences, NextCell-Cord RUO cells have been commercially launched.

NextCell Pharma AB (publ) (“NextCell” or the “Company”) publishes its Annual Report for the extended financial year September 1, 2024 – December 31, 2025. The Annual Report is available in Swedish as an appendix to this press release or on the company's website: www.nextcellpharma.com. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". 

NextCell Pharma AB (publ) (“NextCell” or the “Company”) publishes its Annual Report for the extended financial year September 1, 2024 – December 31, 2025. The Annual Report is available in Swedish as an appendix to this press release or on the company's website: www.nextcellpharma.com. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". 

NextCell Pharma AB (“NextCell” or the “Company”) announces that the Phase II clinical trial evaluating ProTrans® (allogeneic Wharton’s Jelly-derived mesenchymal stromal cells) for respiratory complications associated with COVID-19 has been accepted for publication in Cytotherapy (https://www.isct-cytotherapy.org/article/S1465-3249(26)00736-X/abstract), the official journal of the International Society for Cell & Gene Therapy.

At the Extraordinary General Meeting of NextCell Pharma AB (publ) (“NextCell” or the “Company”) held on 21 August 2025, it was resolved that the Company shall change its financial year from a broken financial year September–August to a calendar year January–December. The Company’s first full financial year in accordance with the calendar year will be 2026. To facilitate historical comparisons and enhance transparency for future reports that will follow the calendar year structure, the Company is today publishing financial information for the five most recent comparative quarters.